Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. mRNA and protein expression for VCN-01 infection and replication targets.
  • Fig. S2. In vitro characterization of VCN-01 activity in retinoblastoma models.
  • Fig. S3. AdTLRGDK genomes in mouse plasma after one intravitreous administration.
  • Fig. S4. In vivo characterization of VCN-01 efficacy and replication.
  • Fig. S5. Macrophage accumulation in the uvea/ciliary body and the inner surface of the retina in VCN-01–treated rabbits.
  • Fig. S6. Human translation of VCN-01 for retinoblastoma treatment.
  • Fig. S7. Histopathology of a VCN-01–treated human eye.
  • Table S3. CAR, α5 integrin, and αv integrin expression scores (high, H; moderate, M; low, L; and negative, N) in tumors in relation to clinicopathologic characteristics of enucleated retinoblastoma patients.
  • Table S4. E2F-1 and RB1 expression score (high, H; moderate, M; low, L; and negative, N) in tumors in relation to clinicopathologic characteristics of enucleated retinoblastoma patients.
  • Table S5. Clinical details of patient-derived retinoblastoma cell models.
  • Table S7. Clinical details for the first two patients of the clinical trial.
  • References (5557)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1. Gene expression in retinoblastoma primary tumors, retinoblastoma cell lines, and fetal retinas (provided as an Excel file).
  • Table S2. Differential gene expression for fetal retinas and retinoblastomas (limma t test) (provided as an Excel file).
  • Table S6. Ocular toxicity monitoring (edema, intraocular pressure, and slit-lamp imaging) in juvenile rabbits treated with VCN-01 (provided as an Excel file).
  • Data file S1. Primary data (provided as an Excel file).